AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4046836 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/twice daily)
Number of subjects: 10
Study 4046836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31183921 — intervention group
Group type: EXPERIMENTAL
Intervention: Eriomin 200 mg
Number of subjects: 103
Study 31183921 — intervention group
Group type: EXPERIMENTAL
Intervention: Eriomin 400 mg
Number of subjects: 103
Study 31183921 — intervention group
Group type: EXPERIMENTAL
Intervention: Eriomin 800 mg
Number of subjects: 103
Study 31183921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 30531444 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone (150 mg dry extract of glycine max) plus probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactococcus lactis, Bifidobacterium bifidum, and Bifidobacterium lactis)
Number of subjects: 60
Study 30531444 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (1 mg estradiol and 0.5 mg norethisterone acetate)
Number of subjects: 60
Study 30531444 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone (150 mg dry extract of glycine max)
Number of subjects: 60
Study 30531444 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 26165565 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-focused educational brochure
Number of subjects: 0
Study 25249300 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA (quartiles 1 to 4)
Number of subjects: 27491
Study 25249300 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP (quartiles 1 to 4)
Number of subjects: 27491
Study 25249300 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA (quartile 4 vs 1 after lipid adjustment)
Number of subjects: 27491
Study 25249300 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP (quartile 4 vs 1 after lipid adjustment)
Number of subjects: 27491
Study 25249300 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA (quartile 4 vs 1 after adjustment for hsCRP)
Number of subjects: 27491
Study 25249300 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP (quartile 4 vs 1 after adjustment for GlycA)
Number of subjects: 27491
Study 22765856 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem (2 mL of 2%)
Number of subjects: 66
Study 22765856 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerine (2 mL of 0.2%)
Number of subjects: 66
Study 22765856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 20331461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation of the anterior nuclei of the thalamus
Number of subjects: 110
Study 20331461 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control group)
Number of subjects: 110
Study 17305268 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Indicator (QI) feedback reports
Number of subjects: 0
Study 17305268 — intervention group
Group type: EXPERIMENTAL
Intervention: APN consultation
Number of subjects: 0
Study 17305268 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement training
Number of subjects: 0
Study 17315409 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg sublingual BUP over one hour (one-day group)
Number of subjects: 20
Study 17315409 — intervention group
Group type: COMPARATOR
Intervention: 32 mg sublingual BUP over three days (three-day group)
Number of subjects: 20
Study 12411795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet during total knee arthroplasty
Number of subjects: 46
Study 12411795 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tourniquet) during total knee arthroplasty
Number of subjects: 46
Study 10511425 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere stimulation
Number of subjects: 0
Study 10511425 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere stimulation
Number of subjects: 0
Study 7779245 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 65
Study 7779245 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 65
Study 7779245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 2313083 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% ethyl alcohol with 0.5% chlorhexidine gluconate (ALC)
Number of subjects: 60
Study 2313083 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid detergent base containing 1% triclosan (TRI)
Number of subjects: 60
Study 2313083 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid detergent base containing 4% chlorhexidine gluconate (CHG)
Number of subjects: 60
Study 2313083 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid detergent base containing 7.5% povidone‐iodine (PI)
Number of subjects: 60
Study 2313083 — intervention group
Group type: COMPARATOR
Intervention: Nonantimicrobial liquid soap (control)
Number of subjects: 60
Study 384025 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 89
Study 384025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 31601585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-based Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 50
Study 31601585 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid therapy
Number of subjects: 50
Study 28359996 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiation
Number of subjects: 40
Study 28359996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same device without laser emission)
Number of subjects: 40
Study 26079842 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly home counseling visits by community support agents
Number of subjects: 400
Study 26079842 — intervention group
Group type: COMPARATOR
Intervention: Posttest counseling alone (routine arm)
Number of subjects: 400
Study 24004815 — intervention group
Group type: EXPERIMENTAL
Intervention: Online decision aid (DA)
Number of subjects: 585
Study 24004815 — intervention group
Group type: COMPARATOR
Intervention: Standard control group
Number of subjects: 585
Study 24004815 — intervention group
Group type: COMPARATOR
Intervention: Three-month control group
Number of subjects: 585
Study 20852001 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Valsartan + HCTZ (triple combination)
Number of subjects: 0
Study 20852001 — intervention group
Group type: COMPARATOR
Intervention: Valsartan + HCTZ (dual combination)
Number of subjects: 0
Study 20852001 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine + Valsartan (dual combination)
Number of subjects: 0
Study 20852001 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine + HCTZ (dual combination)
Number of subjects: 0
Study 19828902 — intervention group
Group type: EXPERIMENTAL
Intervention: Green plantain-based diet (50 g/L)
Number of subjects: 80
Study 19828902 — intervention group
Group type: COMPARATOR
Intervention: Yogurt-based diet
Number of subjects: 80
Study 16731387 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate placement of Frialit‐2 Synchro implants (IP) after extraction
Number of subjects: 50
Study 16731387 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement of Frialit‐2 Synchro implants (DP) after a 3‐month healing period
Number of subjects: 50
Study 16731387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IP and DP implants
Number of subjects: 50
Study 15319854 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced risk-reduction counseling (4 sessions)
Number of subjects: 1766
Study 15319854 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief risk-reduction counseling (2 sessions)
Number of subjects: 1766
Study 15319854 — intervention group
Group type: COMPARATOR
Intervention: Control arm (brief informational messages)
Number of subjects: 1766
Study 11418253 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored office systems for preventive service delivery
Number of subjects: 77
Study 11418253 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 9174877 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin
Number of subjects: 30
Study 9174877 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 30
Study 9174877 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% norfloxacin
Number of subjects: 30
Study 8342439 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg of immediate‐release oral morphine tablets
Number of subjects: 28
Study 8342439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3554084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg X 1 dose of metoclopramide (regimen A)
Number of subjects: 42
Study 3554084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg X 2 doses of metoclopramide (regimen B)
Number of subjects: 42
Study 31921133 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline NKp30 expression
Number of subjects: 12
Study 31921133 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell activation
Number of subjects: 12
Study 31921133 — intervention group
Group type: EXPERIMENTAL
Intervention: NKp30 expression
Number of subjects: 12
Study 30203123 — intervention group
Group type: COMPARATOR
Intervention: Single escalating doses of RN909 (0.3 to 6 mg/kg SC, or 1 mg/kg IV)
Number of subjects: 84
Study 30203123 — intervention group
Group type: COMPARATOR
Intervention: Multiple escalating doses of RN909 (50 to 150 mg SC)
Number of subjects: 84
Study 30203123 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of RN909
Number of subjects: 84
Study 30203123 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of RN909
Number of subjects: 84
Study 30203123 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and multiple doses of RN909
Number of subjects: 84
Study 27600316 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator intervention consisting of 2 in-person sessions about quality performance and viewing scores for local practices; both groups received a pamphlet about health care quality.
Number of subjects: 726
Study 27600316 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a pamphlet about health care quality.
Number of subjects: 726
Study 24812901 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiju Dihuang Pill (QDP) for 2-4 weeks
Number of subjects: 163
Study 24812901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 163
Study 24812901 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiju Dihuang Pill (QDP)
Number of subjects: 163
Study 24829661 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD treatment prior to surgery
Number of subjects: 58
Study 24829661 — intervention group
Group type: COMPARATOR
Intervention: No GERD treatment prior to surgery
Number of subjects: 58
Study 24829661 — intervention group
Group type: COMPARATOR
Intervention: GERD negative patients (control group)
Number of subjects: 58
Study 21609913 — intervention group
Group type: EXPERIMENTAL
Intervention: InterX® transcutaneous dynamic electrical stimulation
Number of subjects: 40
Study 21609913 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual osteopathic therapy
Number of subjects: 40
Study 21609913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 17803999 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial artery flow‐mediated dilation (BFMD)
Number of subjects: 132
Study 16422847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 2102
Study 16422847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 2102
Study 16422847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study 12451006 — intervention group
Group type: EXPERIMENTAL
Intervention: Renovascular disease (RVD) patients
Number of subjects: 75
Study 12451006 — intervention group
Group type: EXPERIMENTAL
Intervention: RVD patients after angioplasty
Number of subjects: 75
Study 12451006 — intervention group
Group type: EXPERIMENTAL
Intervention: RVD patients
Number of subjects: 75
Study 9895062 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane and ketorolac
Number of subjects: 200
Study 9895062 — intervention group
Group type: COMPARATOR
Intervention: halothane and placebo
Number of subjects: 200
Study 9895062 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane and ketorolac
Number of subjects: 200
Study 9895062 — intervention group
Group type: COMPARATOR
Intervention: sevoflurane and placebo
Number of subjects: 200
Study 7546116 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 x 8 mesh nonwoven sponge
Number of subjects: 15
Study 7546116 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 x 13 mesh nonwoven sponge
Number of subjects: 15
Study 7546116 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 x 8 mesh nonwoven sponge
Number of subjects: 15
Study 2286588 — intervention group
Group type: EXPERIMENTAL
Intervention: co-trimoxazole/colistin
Number of subjects: 59
Study 2286588 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin
Number of subjects: 59
Study 2286588 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Number of subjects: 59
Study 7225738 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 82
Study 7225738 — intervention group
Group type: COMPARATOR
Intervention: Phenol injection
Number of subjects: 82
Study 31638594 — intervention group
Group type: EXPERIMENTAL
Intervention: Active education via an app providing day-to-day postoperative care information
Number of subjects: 213
Study 31638594 — intervention group
Group type: COMPARATOR
Intervention: Standard patient education (weekly, basic information)
Number of subjects: 213
Study 28822654 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-tDCS (1 mA, 2 x 5 min)
Number of subjects: 15
Study 28822654 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-tDCS (reversed polarity, 1 mA, 2 x 5 min)
Number of subjects: 15
Study 28822654 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 15
Study 26416253 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based intervention (FB)
Number of subjects: 110
Study 26416253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement intervention (ONS)
Number of subjects: 110
Study 26416253 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 110
Study 23318529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (resistance and aerobic modes); n=29
Number of subjects: 57
Study 23318529 — intervention group
Group type: COMPARATOR
Intervention: Usual care control; n=28
Number of subjects: 57
Study 22003339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal EPAP device
Number of subjects: 41
Study 18971325 — intervention group
Group type: EXPERIMENTAL
Intervention: AVN944 (doses ranging from 25 to 250 mg)
Number of subjects: 25
Study 18971325 — intervention group
Group type: EXPERIMENTAL
Intervention: AVN944 (doses > 100 mg)
Number of subjects: 25
Study 18971325 — intervention group
Group type: EXPERIMENTAL
Intervention: AVN944 (with fasting)
Number of subjects: 25
Study 18971325 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 doses, one with food and one after fasting)
Number of subjects: 25
Study 17762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 42
Study 17762749 — intervention group
Group type: COMPARATOR
Intervention: Reoperation
Number of subjects: 42
Study 15211696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride (CH)
Number of subjects: 18
Study 15211696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11167281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluorometholone acetate (steroid group)
Number of subjects: 80
Study 11167281 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ketorolac tromethamine (NSAID group)
Number of subjects: 80
Study 9778226 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate, sulfasalazine, or both (exact dosages not specified)
Number of subjects: 105
Study 9778226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 105
Study 9778226 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate, sulfasalazine, or both
Number of subjects: 105
Study 8089282 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% FDO
Number of subjects: 0
Study 8089282 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 2842882 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched solution
Number of subjects: 56
Study 2842882 — intervention group
Group type: COMPARATOR
Intervention: Conventional amino acid solution (Control)
Number of subjects: 56
Study 30302877 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 211
Study 30302877 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 211
Study 26685122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg.kg(‐1) (high dose group)
Number of subjects: 50
Study 26685122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg.kg(‐1) (middle dose group)
Number of subjects: 50
Study 26685122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg.kg(‐1) (low dose group)
Number of subjects: 50
Study 25373320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (1,000 mg iron)
Number of subjects: 17
Study 25373320 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 22523159 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin hydrogel (GHG) wound dressing
Number of subjects: 68
Study 20212264 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with aerobic exercise and caloric restriction
Number of subjects: 144
Study 20212264 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet alone
Number of subjects: 144
Study 20212264 — intervention group
Group type: COMPARATOR
Intervention: Usual diet controls (UC)
Number of subjects: 144
Study 18403746 — intervention group
Group type: EXPERIMENTAL
Intervention: PT+AO(congruent)
Number of subjects: 8
Study 18403746 — intervention group
Group type: COMPARATOR
Intervention: PT+AO(incongruent)
Number of subjects: 8
Study 18403746 — intervention group
Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 8
Study 16368047 — intervention group
Group type: EXPERIMENTAL
Intervention: DDTDF (Durogesic D‐TRANS fentanyl Matrix Delivery System)
Number of subjects: 80
Study 16368047 — intervention group
Group type: COMPARATOR
Intervention: Transdermal reservoir system (fentanyl transdermal reservoir)
Number of subjects: 80
Study 12889679 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg/day
Number of subjects: 12
Study 12889679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10471635 — intervention group
Group type: EXPERIMENTAL
Intervention: aerosolized E25 1 mg
Number of subjects: 33
Study 10471635 — intervention group
Group type: EXPERIMENTAL
Intervention: aerosolized E25 10 mg
Number of subjects: 33
Study 10471635 — intervention group
Group type: COMPARATOR
Intervention: aerosolized placebo
Number of subjects: 33
Study 8609344 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (20 g/day for 28 days)
Number of subjects: 20
Study 8609344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle syrup in equal amounts)
Number of subjects: 20
Study 8609344 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy individuals)
Number of subjects: 20
Study 2031820 — intervention group
Group type: COMPARATOR
Intervention: aminophylline 2 mg kg‐1
Number of subjects: 60
Study 2031820 — intervention group
Group type: EXPERIMENTAL
Intervention: flumazenil 0.01 mg kg‐1
Number of subjects: 60
Study 2031820 — intervention group
Group type: COMPARATOR
Intervention: placebo saline 0.1 ml kg‐1
Number of subjects: 60
Study 7013893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-incisional cefuroxime (n = 26)
Number of subjects: 81
Study 7013893 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic cefuroxime (n = 27)
Number of subjects: 81
Study 7013893 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 81
Study 29912679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin (IDC)
Number of subjects: 32
Study 29912679 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (IB)
Number of subjects: 32
Study 29912679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin (IDC) in extremely low-birthweight infants (<1000 g)
Number of subjects: 32
Study 29912679 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (IB) in extremely low-birthweight infants (<1000 g)
Number of subjects: 32
Study 29912679 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (IDC) and Oral ibuprofen (IB)
Number of subjects: 32
Study 27342501 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK+IL-2
Number of subjects: 170
Study 24842181 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intracluster-injection (TII) technique
Number of subjects: 90
Study 24842181 — intervention group
Group type: COMPARATOR
Intervention: Double-injection (DI) technique
Number of subjects: 90
Study 21638755 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox treatment (25 mg/kg/day)
Number of subjects: 20
Study 21638755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron chelation treatment)
Number of subjects: 20
Study 19174783 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise circumferential and focal ablation using the HALO system
Number of subjects: 63
Study 17196682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (4 mg)
Number of subjects: 150
Study 17196682 — intervention group
Group type: COMPARATOR
Intervention: Cocktail (normal saline + 200 microg of verapamil)
Number of subjects: 150
Study 17196682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 150
Study 15190527 — intervention group
Group type: EXPERIMENTAL
Intervention: MVR surgery plus the CorCap Cardiac Support Device (CSD)
Number of subjects: 300
Study 15190527 — intervention group
Group type: EXPERIMENTAL
Intervention: CSD implant plus optimal medical therapy
Number of subjects: 300
Study 15190527 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 300